-
Cabozantinib, sold
under the
brand names Cometriq and
Cabometyx among others, is an anti-cancer
medication used to
treat medullary thyroid cancer, renal...
-
partnered its lead
cancer drug candidate, XL-184 (which
would become called cabozantinib) and
another cancer candidate, XL-281, with
Bristol Myers Squibb; BMS...
- surgery.
Cabozantinib,
trade name Cometriq, was
granted marketing approval (November 2012) by the U.S. FDA for this indication.
Cabozantinib which is...
- daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib,
cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib...
-
common adverse reaction to
cytotoxic chemotherapy drugs,
particularly cabozantinib, cytarabine, doxorubicin, and
fluorouracil and its
prodrug capecitabine...
- cell
carcinoma over
everolimus in 2015 and was
approved by the FDA.
Cabozantinib also
demonstrated an
overall survival benefit over
everolimus and was...
-
ipilimumab combination therapy, or in
combination with
chemotherapy or
cabozantinib. The
approval includes indications for
renal cell carcinoma, melanoma...
- (PNB-0408)
Kinase inhibitors:
Altiratinib AM7 AMG-458
Amuvatinib BMS-777607
Cabozantinib Capmatinib Crizotinib Foretinib Golvatinib INCB28060 JNJ-38877605 K252a...
-
cancer (MTC) who
require systemic therapy following prior treatment with
cabozantinib and/or vandetanib. In
September 2024, the FDA
granted traditional approval...
- (PNB-0408)
Kinase inhibitors:
Altiratinib AM7 AMG-458
Amuvatinib BMS-777607
Cabozantinib Capmatinib Crizotinib Foretinib Golvatinib INCB28060 JNJ-38877605 K252a...
